Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Insider Trading: Daniel Gold’s QVT Financial Sold 650 Thousand Shares in $ANDS

Daniel Gold’s QVT Financial sold 650 thousand shares in Anadys Pharmaceuticals Inc. (ANDS) on October 17th. According to the firm’s Form 4 and amend 13D on October 19th. QVT Financial made a single insider sale of 650 thousand shares, or 1.13% stake at $3.68. Now the firm retains 10.77 million shares in ANDS, corresponding to an 18.84% activist stake. Since QVT Financial reported 11.42 million shares, or 19.97% stake in ANDS in its last 13F filing, this is the firm’s only transaction in ANDS after the second quarter. ANDS had an even path for several months. It suddenly crushed the market on October 17th because ANDS agreed a $230 million buyout offer from Roche. As a result, ANDS skyrocketed by 250% and is now trading at $3.68. 

Six hedge funds revealed their positions in ANDS in the second quarter. Beside QVT Financial’s 11.42 million shares position, Samuel Isaly’s Orbimed Advisors reported 5.30 million shares, giving a 9.27% stake. Phill Gross And Robert Atchinson’s Adage Capital Management had 3.27 million shares, corresponding to a 5.72% stake ownership.

Phill Gross

According to Bloomberg Businessweek, QVT Financial is a privately owned hedge fund sponsor, providing its services to pooled investment vehicles. The firm mainly invests in the public equity and debt markets worldwide. It also invests in alternative investment markets. It uses structured finance, private placements, high yield and distressed debt to create its portfolios. The firm had a portfolio value of more than $1.5 billion as of June 2011.

Anadys Pharmaceuticals, Inc. is a biopharmaceutical company engaged in developing medicines for the treatment of hepatitis C. The Company is developing ANA598 and ANA773, which are used in Phase I and II trial in hepatitis C. In June 2009, the Company initiated a strategic restructuring to focus its operations on the development of ANA598. The company was formerly known as Scriptgen Pharmaceuticals, Inc.before May 2000. The company was founded in 1992 and is headquartered in San Diego, California.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!